Systemic inflammation following cardiopulmonary bypass for mitral valve replacement: the role of non-steroidal anti-inflammatory drugs parecoxib and flurbiprofen.

Trial Profile

Systemic inflammation following cardiopulmonary bypass for mitral valve replacement: the role of non-steroidal anti-inflammatory drugs parecoxib and flurbiprofen.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 May 2012

At a glance

  • Drugs Flurbiprofen (Primary) ; Parecoxib (Primary)
  • Indications Postoperative pain
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top